Sutantatug Envedotin clinical trials
Also written SYS6002 and CRB-701.
How each study uses Sutantatug Envedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Sutantatug Envedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
CSPC Megalith Biopharmaceutical Co.,Ltd. (4) · Corbus Pharmaceuticals Inc. (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Sutantatug Envedotin.
- Jan 2027A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsPhase 1/2 · Corbus Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses Sutantatug Envedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaRecruitingPhase 3Corbus Pharmaceuticals Inc.NCT07768189Written as CRB-701
- SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial CarcinomaNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07526792Written as SYS6002
- SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07374549Written as SYS6002
- A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsRecruitingPhase 1/2Corbus Pharmaceuticals Inc.NCT06265727Written as CRB-701
- SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical CancerNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07230626Written as SYS6002
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06989671Written as SYS6002